Biological Sample Handling Market by Product Type (Consumables, Instruments, Reagents And Kits), Workflow (Analysis, Collection, Processing), Sample Type, Application, End User - Global Forecast 2025-2032
Description
The Biological Sample Handling Market was valued at USD 19.85 billion in 2024 and is projected to grow to USD 21.09 billion in 2025, with a CAGR of 6.62%, reaching USD 33.16 billion by 2032.
A concise orientation to the evolving technical and operational forces reshaping biological sample handling across laboratories and clinical workflows
This executive summary synthesizes contemporary dynamics shaping biological sample handling across laboratories, clinical settings, and lifecycle workflows. It opens with an examination of the technological advancements and operational pressures that are redefining how samples are collected, processed, stored, analyzed, and transported. Through a concise narrative, the content highlights the critical intersections between laboratory automation, reagent specificity, software-enabled traceability, and end-user requirements, offering leaders a rapid orientation to the forces driving change.
The narrative underscores increasing integration across instruments, consumables, reagents and kits, and software and services, and explains how these components collectively influence throughput, reproducibility, and regulatory compliance. Additionally, the introduction sets expectations for subsequent sections by outlining key segmentation lenses-product type, end user, application, sample type, and workflow-that structure the analysis. It clarifies the analytic approach and prepares readers to evaluate strategic implications specific to their operational footprint, whether in academic research, diagnostics, biopharma development, or clinical laboratories.
Finally, the introduction frames the imperative for actionable intelligence: in a context where precision, speed, and traceability matter more than ever, decision-makers must align procurement, R&D, and quality systems to capture value from evolving technologies and regulatory expectations.
How automation, data-first workflows, and supply chain resilience are jointly transforming sample handling practices and shaping long-term operational priorities
The landscape of biological sample handling is undergoing transformative shifts driven by a combination of automation adoption, data-centric workflows, and heightened regulatory scrutiny. Emerging automation solutions reduce manual variability and enable higher throughput, while software platforms introduce real-time tracking, audit trails, and analytics that support reproducibility and compliance. At the same time, reagent and kit innovations enhance assay sensitivity and robustness, enabling downstream workflows such as genomics and proteomics to deliver more reliable outputs.
Concurrently, supply chain resiliency has moved from a tactical concern to a strategic priority, prompting laboratories and manufacturers to rethink sourcing, inventory management, and supplier diversification. Furthermore, cross-disciplinary collaboration between diagnostic laboratories, biopharmaceutical firms, and academic institutions accelerates technology translation and drives demand for interoperable instruments and consumables. These shifts are persistent rather than episodic, and they compel stakeholders to re-evaluate procurement strategies, validation pipelines, and lifecycle support programs.
In addition, the rise of decentralized testing and point-of-care modalities has created new requirements for sample stability, transport media, and simplified processing devices. Taken together, these transformative dynamics mandate that organizations balance innovation adoption with robust quality systems and clear regulatory engagement to sustain performance improvements and market differentiation.
Assessment of 2025 tariff-driven supply chain adjustments and procurement strategies that have reshaped cost structures and supplier relationships in sample handling
Tariff changes implemented in 2025 have had a measurable influence on the operational calculus of organizations that rely on cross-border flows of instruments, consumables, reagents, and specialized components. Increased duties on certain laboratory equipment and imported reagents altered landed costs, prompting procurement teams to reassess supplier portfolios and shipping models. In response, many organizations extended lead times, negotiated longer-term contracts with incumbent suppliers, and explored nearshoring options to mitigate exposure to tariff volatility.
Moreover, the tariff environment heightened attention to total cost of ownership rather than unit price alone. Laboratories and manufacturers began to evaluate maintenance contracts, spare parts availability, and software licensing structures in the context of higher import-related expenses. This shift encouraged greater consolidation of supplier relationships and an emphasis on vendor partnerships that provide integrated lifecycle services and local technical support. At the same time, some vendors accelerated efforts to regionalize manufacturing and qualify alternative sources for reagents and critical subcomponents, thereby reducing the susceptibility of operations to future trade policy changes.
Regulatory compliance and documentation requirements for customs classification gained prominence as procurement and compliance teams worked to avoid misclassification penalties. In sum, the cumulative effect of the 2025 tariff adjustments has been to increase the strategic importance of supply chain transparency, supplier resilience, and collaborative commercial arrangements that smooth cost and availability impacts across laboratory networks.
Detailed segmentation analysis revealing where instrument specialization, reagent complexity, end-user profiles, and workflow stages converge to shape purchasing decisions
The market structure can be meaningfully interpreted through layered segmentation that clarifies where investment and innovation concentrate. Based on product type, the ecosystem spans consumables, instruments, reagents and kits, and software and services. Within instruments, there is particular focus on automated pipetting systems, temperature-controlled centrifuges, and vortex mixers, each of which addresses distinct throughput and reproducibility requirements. Reagents and kits break down into antibodies, buffers and solutions, enzymes, and labeling and detection reagents, categories that determine assay performance and shelf-life management.
Based on end user, demand patterns differ across academic and research institutes, biopharmaceutical companies, contract research organizations, diagnostic laboratories, and hospitals. Diagnostic laboratories further diversify into clinical chemistry, hematology, microbiology, and molecular diagnostics, reflecting specialized instrumentation and consumable profiles. Based on application, usage distinguishes diagnostics, drug discovery and development, genomics, and proteomics, with diagnostics further bifurcated into laboratory diagnostics and point-of-care environments, each with unique requirements for speed, robustness, and regulatory oversight.
Based on sample type, workflows adapt to blood, cells, tissue, and urine, where pre-analytical handling, preservation, and transport dictate protocol choices. Based on workflow, the market organizes around analysis, collection, processing, storage, and transport, and each stage requires tailored solutions that prioritize integrity, traceability, and compatibility across vendor portfolios. By interpreting these segmentation lenses together, stakeholders can better map capability gaps, prioritize investments, and tailor commercial approaches to distinct customer segments and technical constraints.
Comparative regional dynamics that determine procurement priorities, regulatory alignment, and local manufacturing choices across major global markets
Regional dynamics exert strong influence over procurement practices, regulatory expectations, and operational design in biological sample handling. In the Americas, investment in advanced laboratory automation and clinical diagnostics remains robust, fueled by significant research infrastructure and a dense network of diagnostic laboratories and biopharmaceutical firms. This environment fosters demand for high-throughput instruments, validated reagent workflows, and software that supports quality management and data integration across multi-site operations.
In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and healthcare infrastructure creates a mosaic of adoption patterns. Some markets emphasize stringent regulatory compliance and provenance tracking, while others prioritize affordability and supply chain adaptability. Consequently, vendors often employ flexible commercial models and region-specific validation services to accommodate varied customer capabilities and reimbursement environments. Finally, in Asia-Pacific, rapid expansion in research capacity, increasing clinical diagnostics deployment, and strategic investment in local manufacturing capacity have accelerated demand for both core laboratory instruments and consumables that can be sourced regionally. This region also demonstrates fast uptake of point-of-care solutions and cost-efficient reagent kits.
Taken together, these regional insights inform decisions about where to locate manufacturing, how to structure commercial presence, and which regulatory and validation resources to prioritize when expanding distribution or supporting local partners.
How market leaders and specialized innovators are differentiating through integrated solutions, local support, and partnerships to drive laboratory adoption
Key companies operating in the biological sample handling space are distinguishing themselves through complementary strategies that combine product portfolio breadth, service capabilities, and partnerships. Industry leaders invest in integrated solutions that bundle instruments with validated reagents, workflow consumables, and software-enabled traceability to reduce implementation friction for customers. They also expand service footprints to include preventative maintenance, training programs, and remote diagnostics, thereby enhancing uptime and reducing total operational risk for laboratory clients.
Mid-sized firms and specialized providers are carving differentiation through nimble innovation cycles, focusing on niche instrumentation like automated pipetting platforms or temperature-controlled centrifuges, and developing reagent chemistries optimized for high-sensitivity applications. Strategic collaborations between instrument manufacturers and reagent developers accelerate time-to-qualification for new assays, while alliances with software vendors enable richer data capture and regulatory reporting. Additionally, companies that demonstrate supply chain transparency and localized inventory management gain traction with customers seeking resilience against trade and logistics disruptions.
Overall, competitive positioning increasingly depends on the ability to provide end-to-end validated solutions that simplify laboratory adoption and deliver measurable improvements in reproducibility, throughput, and compliance.
Targeted actions executives can take to strengthen resilience, accelerate automation adoption, and align commercial strategies with regulatory and regional realities
Industry leaders should adopt a pragmatic, multi-dimensional agenda that balances short-term resilience with long-term capability building. First, strengthen supplier diversification and inventory visibility to mitigate exposure to tariff and logistics disruptions while ensuring continuity of critical reagents and instrument components. Second, accelerate validation pathways for automation and software platforms, prioritizing interoperability and standardized data outputs that simplify integration across multi-vendor laboratory environments. These steps will reduce operational friction and support reproducible results.
Third, invest in workforce training and remote support infrastructure to maximize the value of automated platforms and to maintain quality oversight in distributed testing environments. Fourth, pursue strategic partnerships that combine instrument, reagent, and software competencies to offer customers validated, end-to-end workflows; such collaborations shorten qualification cycles and lower adoption barriers. Fifth, localize manufacturing and service capabilities where regulatory and trade dynamics present sustained cost or delivery advantages, thereby improving responsiveness to regional customers.
Finally, engage proactively with regulators and standards bodies to shape practical guidance for sample handling, traceability, and data management. By executing on these recommendations, organizations can enhance operational reliability, improve customer retention, and create embeddable capabilities that support future innovations in diagnostics, genomics, and therapeutic development.
Transparent mixed-methods research approach combining primary stakeholder interviews, technical validation reviews, and rigorous secondary-source triangulation
The research underpinning this report employed a mixed-methods approach that combined primary stakeholder interviews, technical validation reviews, and comprehensive secondary-source synthesis. Primary inputs included structured discussions with laboratory managers, procurement leaders, instrument engineers, quality assurance specialists, and product managers across academic, clinical, and commercial settings. These engagements clarified practical pain points in pre-analytical handling, instrument lifecycle management, and supplier interactions, and they informed interpretation of vendor strategies and customer priorities.
Secondary analysis drew upon peer-reviewed literature, regulatory guidance documents, standards publications, and supplier technical literature to validate functional claims regarding instrument performance, reagent stability, and software capabilities. Where possible, methodology emphasized cross-validation across multiple independent sources to minimize bias and to ensure robustness. In addition, the study examined trade policy developments and logistics indicators to assess how external forces such as tariffs and supply chain disruptions influence procurement and operational decisions.
Throughout the research process, attention focused on transparency of assumptions, traceability of data inputs, and the practical relevance of findings. The methodology therefore supports actionable insights that are grounded in both technical detail and real-world constraints faced by laboratories and manufacturers.
Synthesis of strategic imperatives emphasizing integration of automation, reagent reliability, and supply chain transparency to enhance laboratory performance
In conclusion, biological sample handling is at an inflection point where operational rigor, automation, and data-driven traceability together determine laboratory performance and competitive differentiation. The convergence of improved instruments, refined reagent chemistries, and software-enabled quality systems creates opportunities for organizations to enhance reproducibility and scale complex workflows across diverse end users. At the same time, geopolitical and trade developments have reinforced the need for supply chain transparency and strategic sourcing approaches that reduce vulnerability to external shocks.
Looking ahead, stakeholders that prioritize integrated solutions, invest in workforce enablement, and localize critical capabilities will be better positioned to capture value from advances in diagnostics, genomics, and drug development workflows. Importantly, progress requires sustained collaboration across manufacturers, reagent suppliers, software vendors, and regulatory bodies to ensure that innovations translate into reliable and compliant laboratory practices. With the right combination of tactical measures and strategic investments, laboratories and their partners can achieve greater efficiency, higher data integrity, and more responsive operational models that support scientific and clinical goals.
Note: PDF & Excel + Online Access - 1 Year
A concise orientation to the evolving technical and operational forces reshaping biological sample handling across laboratories and clinical workflows
This executive summary synthesizes contemporary dynamics shaping biological sample handling across laboratories, clinical settings, and lifecycle workflows. It opens with an examination of the technological advancements and operational pressures that are redefining how samples are collected, processed, stored, analyzed, and transported. Through a concise narrative, the content highlights the critical intersections between laboratory automation, reagent specificity, software-enabled traceability, and end-user requirements, offering leaders a rapid orientation to the forces driving change.
The narrative underscores increasing integration across instruments, consumables, reagents and kits, and software and services, and explains how these components collectively influence throughput, reproducibility, and regulatory compliance. Additionally, the introduction sets expectations for subsequent sections by outlining key segmentation lenses-product type, end user, application, sample type, and workflow-that structure the analysis. It clarifies the analytic approach and prepares readers to evaluate strategic implications specific to their operational footprint, whether in academic research, diagnostics, biopharma development, or clinical laboratories.
Finally, the introduction frames the imperative for actionable intelligence: in a context where precision, speed, and traceability matter more than ever, decision-makers must align procurement, R&D, and quality systems to capture value from evolving technologies and regulatory expectations.
How automation, data-first workflows, and supply chain resilience are jointly transforming sample handling practices and shaping long-term operational priorities
The landscape of biological sample handling is undergoing transformative shifts driven by a combination of automation adoption, data-centric workflows, and heightened regulatory scrutiny. Emerging automation solutions reduce manual variability and enable higher throughput, while software platforms introduce real-time tracking, audit trails, and analytics that support reproducibility and compliance. At the same time, reagent and kit innovations enhance assay sensitivity and robustness, enabling downstream workflows such as genomics and proteomics to deliver more reliable outputs.
Concurrently, supply chain resiliency has moved from a tactical concern to a strategic priority, prompting laboratories and manufacturers to rethink sourcing, inventory management, and supplier diversification. Furthermore, cross-disciplinary collaboration between diagnostic laboratories, biopharmaceutical firms, and academic institutions accelerates technology translation and drives demand for interoperable instruments and consumables. These shifts are persistent rather than episodic, and they compel stakeholders to re-evaluate procurement strategies, validation pipelines, and lifecycle support programs.
In addition, the rise of decentralized testing and point-of-care modalities has created new requirements for sample stability, transport media, and simplified processing devices. Taken together, these transformative dynamics mandate that organizations balance innovation adoption with robust quality systems and clear regulatory engagement to sustain performance improvements and market differentiation.
Assessment of 2025 tariff-driven supply chain adjustments and procurement strategies that have reshaped cost structures and supplier relationships in sample handling
Tariff changes implemented in 2025 have had a measurable influence on the operational calculus of organizations that rely on cross-border flows of instruments, consumables, reagents, and specialized components. Increased duties on certain laboratory equipment and imported reagents altered landed costs, prompting procurement teams to reassess supplier portfolios and shipping models. In response, many organizations extended lead times, negotiated longer-term contracts with incumbent suppliers, and explored nearshoring options to mitigate exposure to tariff volatility.
Moreover, the tariff environment heightened attention to total cost of ownership rather than unit price alone. Laboratories and manufacturers began to evaluate maintenance contracts, spare parts availability, and software licensing structures in the context of higher import-related expenses. This shift encouraged greater consolidation of supplier relationships and an emphasis on vendor partnerships that provide integrated lifecycle services and local technical support. At the same time, some vendors accelerated efforts to regionalize manufacturing and qualify alternative sources for reagents and critical subcomponents, thereby reducing the susceptibility of operations to future trade policy changes.
Regulatory compliance and documentation requirements for customs classification gained prominence as procurement and compliance teams worked to avoid misclassification penalties. In sum, the cumulative effect of the 2025 tariff adjustments has been to increase the strategic importance of supply chain transparency, supplier resilience, and collaborative commercial arrangements that smooth cost and availability impacts across laboratory networks.
Detailed segmentation analysis revealing where instrument specialization, reagent complexity, end-user profiles, and workflow stages converge to shape purchasing decisions
The market structure can be meaningfully interpreted through layered segmentation that clarifies where investment and innovation concentrate. Based on product type, the ecosystem spans consumables, instruments, reagents and kits, and software and services. Within instruments, there is particular focus on automated pipetting systems, temperature-controlled centrifuges, and vortex mixers, each of which addresses distinct throughput and reproducibility requirements. Reagents and kits break down into antibodies, buffers and solutions, enzymes, and labeling and detection reagents, categories that determine assay performance and shelf-life management.
Based on end user, demand patterns differ across academic and research institutes, biopharmaceutical companies, contract research organizations, diagnostic laboratories, and hospitals. Diagnostic laboratories further diversify into clinical chemistry, hematology, microbiology, and molecular diagnostics, reflecting specialized instrumentation and consumable profiles. Based on application, usage distinguishes diagnostics, drug discovery and development, genomics, and proteomics, with diagnostics further bifurcated into laboratory diagnostics and point-of-care environments, each with unique requirements for speed, robustness, and regulatory oversight.
Based on sample type, workflows adapt to blood, cells, tissue, and urine, where pre-analytical handling, preservation, and transport dictate protocol choices. Based on workflow, the market organizes around analysis, collection, processing, storage, and transport, and each stage requires tailored solutions that prioritize integrity, traceability, and compatibility across vendor portfolios. By interpreting these segmentation lenses together, stakeholders can better map capability gaps, prioritize investments, and tailor commercial approaches to distinct customer segments and technical constraints.
Comparative regional dynamics that determine procurement priorities, regulatory alignment, and local manufacturing choices across major global markets
Regional dynamics exert strong influence over procurement practices, regulatory expectations, and operational design in biological sample handling. In the Americas, investment in advanced laboratory automation and clinical diagnostics remains robust, fueled by significant research infrastructure and a dense network of diagnostic laboratories and biopharmaceutical firms. This environment fosters demand for high-throughput instruments, validated reagent workflows, and software that supports quality management and data integration across multi-site operations.
In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and healthcare infrastructure creates a mosaic of adoption patterns. Some markets emphasize stringent regulatory compliance and provenance tracking, while others prioritize affordability and supply chain adaptability. Consequently, vendors often employ flexible commercial models and region-specific validation services to accommodate varied customer capabilities and reimbursement environments. Finally, in Asia-Pacific, rapid expansion in research capacity, increasing clinical diagnostics deployment, and strategic investment in local manufacturing capacity have accelerated demand for both core laboratory instruments and consumables that can be sourced regionally. This region also demonstrates fast uptake of point-of-care solutions and cost-efficient reagent kits.
Taken together, these regional insights inform decisions about where to locate manufacturing, how to structure commercial presence, and which regulatory and validation resources to prioritize when expanding distribution or supporting local partners.
How market leaders and specialized innovators are differentiating through integrated solutions, local support, and partnerships to drive laboratory adoption
Key companies operating in the biological sample handling space are distinguishing themselves through complementary strategies that combine product portfolio breadth, service capabilities, and partnerships. Industry leaders invest in integrated solutions that bundle instruments with validated reagents, workflow consumables, and software-enabled traceability to reduce implementation friction for customers. They also expand service footprints to include preventative maintenance, training programs, and remote diagnostics, thereby enhancing uptime and reducing total operational risk for laboratory clients.
Mid-sized firms and specialized providers are carving differentiation through nimble innovation cycles, focusing on niche instrumentation like automated pipetting platforms or temperature-controlled centrifuges, and developing reagent chemistries optimized for high-sensitivity applications. Strategic collaborations between instrument manufacturers and reagent developers accelerate time-to-qualification for new assays, while alliances with software vendors enable richer data capture and regulatory reporting. Additionally, companies that demonstrate supply chain transparency and localized inventory management gain traction with customers seeking resilience against trade and logistics disruptions.
Overall, competitive positioning increasingly depends on the ability to provide end-to-end validated solutions that simplify laboratory adoption and deliver measurable improvements in reproducibility, throughput, and compliance.
Targeted actions executives can take to strengthen resilience, accelerate automation adoption, and align commercial strategies with regulatory and regional realities
Industry leaders should adopt a pragmatic, multi-dimensional agenda that balances short-term resilience with long-term capability building. First, strengthen supplier diversification and inventory visibility to mitigate exposure to tariff and logistics disruptions while ensuring continuity of critical reagents and instrument components. Second, accelerate validation pathways for automation and software platforms, prioritizing interoperability and standardized data outputs that simplify integration across multi-vendor laboratory environments. These steps will reduce operational friction and support reproducible results.
Third, invest in workforce training and remote support infrastructure to maximize the value of automated platforms and to maintain quality oversight in distributed testing environments. Fourth, pursue strategic partnerships that combine instrument, reagent, and software competencies to offer customers validated, end-to-end workflows; such collaborations shorten qualification cycles and lower adoption barriers. Fifth, localize manufacturing and service capabilities where regulatory and trade dynamics present sustained cost or delivery advantages, thereby improving responsiveness to regional customers.
Finally, engage proactively with regulators and standards bodies to shape practical guidance for sample handling, traceability, and data management. By executing on these recommendations, organizations can enhance operational reliability, improve customer retention, and create embeddable capabilities that support future innovations in diagnostics, genomics, and therapeutic development.
Transparent mixed-methods research approach combining primary stakeholder interviews, technical validation reviews, and rigorous secondary-source triangulation
The research underpinning this report employed a mixed-methods approach that combined primary stakeholder interviews, technical validation reviews, and comprehensive secondary-source synthesis. Primary inputs included structured discussions with laboratory managers, procurement leaders, instrument engineers, quality assurance specialists, and product managers across academic, clinical, and commercial settings. These engagements clarified practical pain points in pre-analytical handling, instrument lifecycle management, and supplier interactions, and they informed interpretation of vendor strategies and customer priorities.
Secondary analysis drew upon peer-reviewed literature, regulatory guidance documents, standards publications, and supplier technical literature to validate functional claims regarding instrument performance, reagent stability, and software capabilities. Where possible, methodology emphasized cross-validation across multiple independent sources to minimize bias and to ensure robustness. In addition, the study examined trade policy developments and logistics indicators to assess how external forces such as tariffs and supply chain disruptions influence procurement and operational decisions.
Throughout the research process, attention focused on transparency of assumptions, traceability of data inputs, and the practical relevance of findings. The methodology therefore supports actionable insights that are grounded in both technical detail and real-world constraints faced by laboratories and manufacturers.
Synthesis of strategic imperatives emphasizing integration of automation, reagent reliability, and supply chain transparency to enhance laboratory performance
In conclusion, biological sample handling is at an inflection point where operational rigor, automation, and data-driven traceability together determine laboratory performance and competitive differentiation. The convergence of improved instruments, refined reagent chemistries, and software-enabled quality systems creates opportunities for organizations to enhance reproducibility and scale complex workflows across diverse end users. At the same time, geopolitical and trade developments have reinforced the need for supply chain transparency and strategic sourcing approaches that reduce vulnerability to external shocks.
Looking ahead, stakeholders that prioritize integrated solutions, invest in workforce enablement, and localize critical capabilities will be better positioned to capture value from advances in diagnostics, genomics, and drug development workflows. Importantly, progress requires sustained collaboration across manufacturers, reagent suppliers, software vendors, and regulatory bodies to ensure that innovations translate into reliable and compliant laboratory practices. With the right combination of tactical measures and strategic investments, laboratories and their partners can achieve greater efficiency, higher data integrity, and more responsive operational models that support scientific and clinical goals.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Adoption of single-use bioprocessing technologies to minimize cross-contamination in biologics manufacturing
- 5.2. Implementation of IoT-enabled cold chain monitoring devices for real-time sample integrity tracking across supply chains
- 5.3. Expansion of decentralized point-of-care testing requiring robust sample stabilization and transport solutions
- 5.4. Development of cryogenic sample preservation methods leveraging novel cryoprotectants to improve long-term viability
- 5.5. Growth of laboratory automation platforms integrating AI-driven quality control for sample handling and data management
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Biological Sample Handling Market, by Product Type
- 8.1. Consumables
- 8.2. Instruments
- 8.2.1. Automated Pipetting Systems
- 8.2.2. Temperature Controlled Centrifuges
- 8.2.3. Vortex Mixers
- 8.3. Reagents And Kits
- 8.3.1. Antibodies
- 8.3.2. Buffers And Solutions
- 8.3.3. Enzymes
- 8.3.4. Labeling And Detection Reagents
- 8.4. Software And Services
- 9. Biological Sample Handling Market, by Workflow
- 9.1. Analysis
- 9.2. Collection
- 9.3. Processing
- 9.4. Storage
- 9.5. Transport
- 10. Biological Sample Handling Market, by Sample Type
- 10.1. Blood
- 10.2. Cells
- 10.3. Tissue
- 10.4. Urine
- 11. Biological Sample Handling Market, by Application
- 11.1. Diagnostics
- 11.1.1. Laboratory Diagnostics
- 11.1.2. Point Of Care
- 11.2. Drug Discovery And Development
- 11.3. Genomics
- 11.4. Proteomics
- 12. Biological Sample Handling Market, by End User
- 12.1. Academic And Research Institutes
- 12.2. Biopharmaceutical Companies
- 12.3. Contract Research Organizations
- 12.4. Diagnostic Laboratories
- 12.4.1. Clinical Chemistry
- 12.4.2. Hematology
- 12.4.3. Microbiology
- 12.4.4. Molecular Diagnostics
- 12.5. Hospitals
- 13. Biological Sample Handling Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Biological Sample Handling Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Biological Sample Handling Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Accelerated Laboratory Logistics
- 16.3.2. Alliance Pharma PLC
- 16.3.3. Azenta Life Sciences
- 16.3.4. BioDock Limited
- 16.3.5. BioLife Solutions Inc.
- 16.3.6. Clinigen Group
- 16.3.7. Cryoniss
- 16.3.8. Cryoport Systems, LLC
- 16.3.9. Discovery Life Sciences
- 16.3.10. Eppendorf SE
- 16.3.11. Hamilton Company
- 16.3.12. Infiuss Health
- 16.3.13. Labtoo
- 16.3.14. Marken by United Parcel Service, Inc.
- 16.3.15. Mercury Business Services
- 16.3.16. MLM Medical Labs
- 16.3.17. Oximio
- 16.3.18. PrecisionMed, LLC
- 16.3.19. ReproCELL Inc.
- 16.3.20. SAROUTE Co., Ltd.
- 16.3.21. SPT Labtech Ltd.
- 16.3.22. Thermo Fisher Scientific Inc.
- 16.3.23. Ziath Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
